Keay Nakae Recent News
Chardan Starts Coverage Of Mesoblast, Sees 'Large Market Opportunities'
StemCells Is Restructuring To Save Cash, But What's That Mean For Investors?
Chardan Initiates Eyegate Pharma At Buy, Sets $6 Target
Chardan Starts Opexa Therapeutics With Buy Rating, $6 Price Target
Should Investors Take The Dive In Nanosphere?
Time To Buy Signal Genetics? Chardan Thinks So
Chardan Capital Markets Reiterates On Medical Transcription Billing
UPDATE: Ascendiant Capital Markets Initiates Coverage On Aldeyra Therapeutics On Intriguing Investment Story
UPDATE: Ascendiant Capital Markets Reiterates On Repros Therapeutics Following Positive Topline Results
UPDATE: Ascendiant Capital Markets Upgrades Pozen Following Q2 Results
UPDATE: Ascendiant Capital Markets Initiates Coverage On Alliqua As Turnaround Story Warrants Fresh Look
UPDATE: Ascendiant Capital Markets Downgrades PhotoMedex Following Completion Of LCA Vision Acquisition
UPDATE: Ascendiant Capital Markets Downgrades Repros Therapeutics Following Announcement of FDA Concerns
UPDATE: Ascendiant Capital Initiates Coverage on Galectin Therapeutics on Intriguing Speculative Short-Cap Investment Story